| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6085cc981958ccb9f6c9c0b5ead9f539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f91655a2c4a2a8b04ba4adbd85a11de2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8e7cb5a043c5fc4ef0517627385e699 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate |
2008-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f82811fa5a4f00e82567abf330f8a9fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c296c11c4ebdd54530f914ad5018c6cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_860bb2d6ac67fda2250c109ac8b02c18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bda0496b4d485a1726eca90100f85453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cb0282b3168becca9327ffd78df7540 |
| publicationDate |
2010-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20100114880-A |
| titleOfInvention |
Use of phthalimide derivatives in the treatment of diseases |
| abstract |
The present invention relates to the use of phthalimide and / or sulfonamide derivatives having nitric oxide donor properties, which are effective in the reduction of TNF-α levels and in the treatment of blood diseases requiring exogenous nitric oxide sources. Have activity important for augmenting and anti-inflammatory and analgesic activity. More particularly, the present invention describes the use of said phthalimide and / or sulfonamide derivatives for the treatment of sickle cell disease. The invention also features a novel feature of the disclosure of novel functionalized phthalimide derivatives designed from circular thalidomide and hydroxyurea and reasonably designed through a molecular hybridization strategy for the treatment of the disease. The present invention also discloses a novel method for obtaining specific sulfonamide derivatives that can be used for the preparation of drugs for the reduction of TNF-α factor levels and for the treatment of diseases in which exogenous nitric oxide sources are required. |
| priorityDate |
2007-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |